LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.79 USD | +14.18% |
|
+17.97% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.73M | Capitalization | 454M |
|---|---|---|---|---|---|
| Net income 2024 * | -52M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 67.5 x |
| P/E ratio 2024 * |
-6.35
x | P/E ratio 2025 * |
-7.42
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +14.18% | ||
| 1 week | +17.97% | ||
| Current month | +16.35% | ||
| 1 month | +13.10% |
1 week
14.49
18.83
1 month
14.4219.92
Current year
14.4224.59
1 year
14.4224.59
3 years
14.4224.59
5 years
14.4224.59
10 years
14.4224.59
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 17.79 | +14.18% | 338,112 |
| 24-06-07 | 15.58 | +3.59% | 57,788 |
| 24-06-06 | 15.04 | -6.76% | 163,048 |
| 24-06-05 | 16.13 | +9.88% | 179,751 |
| 24-06-04 | 14.68 | -2.65% | 189,975 |
Delayed Quote Nasdaq, June 10, 2024 at 04:00 pm EDT
More quotes
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Calendar
2024-06-18
- Investor Meeting - Key Opinion Leader
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.79
USD
Average target price
35.6
USD
Spread / Average Target
+100.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 454M | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 23.64B | |
| +3.09% | 22.39B | |
| -11.25% | 17.78B | |
| -41.74% | 16.43B | |
| -13.47% | 16.34B | |
| +2.23% | 13.56B | |
| +27.13% | 11.59B |
- Stock Market
- Equities
- LENZ Stock
